Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eisai has signed a Japan licensing pact with Minophagen Pharmaceutical for the treatment of cutaneous T-cell lymphoma (CTCL), Bexarotene (generic name).
Subscribe to our email newsletter
As per the terms of the agreement, Minophagen is expected to get license for the development and commercialization of Eisai‘s Bexarotene in Japan.
However, Eisai is expected to hold the option to co-promote the product in Japan, if and when it is approved.
Eisai has acquired Bexarotene from Ligand Pharmaceuticals in October 2006.